NCT03896152View on ClinicalTrials.gov

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 5, 2019

Primary Completion Date

April 7, 2020

Study Completion Date

February 9, 2022

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

LNP023

approximately 2 year of Treatment with LNP023

Trial Locations (5)

10002

Novartis Investigative Site, Taipei

88586

Novartis Investigative Site, Kota Kinabalu

119228

Novartis Investigative Site, Singapore

03080

Novartis Investigative Site, Seoul

06351

Novartis Investigative Site, Seoul

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY